Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2007-05-22
2007-05-22
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S001690
Reexamination Certificate
active
10724397
ABSTRACT:
The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
REFERENCES:
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 5641471 (1997-06-01), Geerlings
patent: WO 96/29087 (1996-09-01), None
patent: WO 96/40245 (1996-12-01), None
patent: WO 96/40425 (1996-12-01), None
Shaun B. Jones et al., Evaluation of Dithiol Chelating Agents as potential Adjuvants for Anti-IL-2 Receptor Lead or Bismuth Alpha Radioimmunotherapy. Nucl. Med. & Biol, vol. 23, 105-113, 1996.
Casey, J. L., et al., “Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle” British Journal of Cancer (1998) 78(10), 1307-1312 XP-000986994.
Rowlinson-Busza, Gail, et al., “90Y-Labeled Antibody Uptake by Human Tumor Xenografts and The Effect of Systemic Administration of EDTA” Int. J. Radiation Oncology Biol. Phys., vol. 28, No. 5, pp. 1257-1265 1994.
Denardo, Sally J., et al., “Yttrium-90/Indium-111-DOTA-Peptide-Chimeric L6: Pharmacokinetics, Dosimetry and Initial Results in Patients with Incurable Breast Cancer” Anticancer Research 17: 1735-1744 (1997).
Adams, G. P., et al., “Delivery of the a-Emitting Radioisotope Bismuth-213 to Sold tumors via Single-Chain Fv and Diabody Molecules” Nuclear Medicine & Biology, vol. 27, pp. 339-348, 2000.
Behr, Thomas M., et al., “High-Linear Energy Transfer (LET) a versus Low-LET B Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model” Cancer Research 59, 2635-2643, Jun. 1, 1999.
Govindan, Serengulam V., et al., “90 Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution Studies” Bioconjugate Chem. 1998, 9, 773-782.
Wong, Jeffrey Y. C., et al., “A Phase I Radioimmunotherapy Trial Evaluating 90 Yttrium-labeled Anti-Carcinoembryonic antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies” Clinical Cancer Research, vol. 6, 3855-3883, Oct. 2000.
Davis, Ila A. et al., “Radioimmunotherapy Using Vascular Targeted 213Bi: The Role of Tumor Necrosis Factor a in the Development of Pulmonary Fibrosis” Clinical Cancer Research 3160s vol. 5, 3160s-3164s, Oct. 1999 (Suppl.).
Watanabe, Naoyuki, et al., “CaNa2 EDTA for Improvement of Radioimmunodetection and Radioimmunotherapy with 111in and 90Y-DTPA-Anti-CEA MAbs in Nude Mice Bearing Human Colorectal Cancer” The Journal of Nuclear Medicine, vol. 41, No. 2, Feb. 2000, pp. 338-344.
Jones, Shaun B. et al. “Evaluation of Dithiol Chelating Agents as Potential Adjuvants for Anti-IL-2 Receptor Lead or Bismuth Alpha Radioimmunotherapy” Nuclear Medicine & Biology, vol. 23, pp. 105-113, 1996.
Goodwin, D. A., et al., “Monosional antibody hapten radiopharmaceutical delivery” Nuclear Medicine Communications 7, 569-580 (1986).
Juweid, Malik E., et al., “Phase I/II Trial of 131I-MN-14 F(ab)2 Anti-Carcinoembryonic Antigen Monoclonal Antibody in the Treatment of Patents with Metastatic Medullary Thyroid Carcinoma” Cancer Apr. 15, 1999, vol. 85, No. 8, p. 1828-1842.
Karacay, et al., “Development of a Streptavidin-Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretergeting Method for Radioimmunotherapy of Colorectal Cancer. Reagent Development” Bioconjugate Chem. 1997, 8, 585-594.
Behr, Thomas M., et al., “Phase I/II Clinical Radioimmunotherapy with an Iodine-131-Labeled Anti-Carcinoembryonic antigen Murine Monoclonal Antibody IgG” The Journal of Nuclear Medicine, vol. 38, No. 6, Jun. 1997, pp. 858-870.
Ullen, Anders, et al. “Use of Anticytokeratin Monoclonal Anti-Idiotypic Antibodies to Improve Tumor: Nontumor Ratio in Experimental Radioimmunolocalization” Cancer Research (Suppl.) 55, 5868s-5873s, Dec. 1, 1995.
Ong, Gaik Lin, et al. “The fate of antibodies and their radiolabels bound to tumor cells in vitro: the effect of cross-linking at the cell surface and of anti-idiotype antibodies” Cancer Immunol Immunotherapy (1994) 39: 325-331.
Sharkey, Robert M., et al., “Clinical Evaluation of Tumor Targeting with a High-Affinity, Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14” Cancer Mar. 15, 1993, vol. 71, No. 6 pp. 2082-2846.
Pimm, M. V., et al. “Influence of syngeneic monoclonal anti-idiotypic antibodies to murine Monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments” J Cancer Res Clinical Oncology (1993) 119:408-414 pp. 408-414.
Schiele, J., et al., “The effect of unlabeled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotype mAb in murine B cell lymphoma” Radiotherapy and Oncology. 24 (1992) 169-176 pp. 169-176.
Sharkey, Robert M., et al., “Enhanced Clearance of Radiolabeled Murine Monoclonal Antibody by a Syngeneic Anti-Idiotype Antibody in Tumor-Bearing Nude Mice” Int. J. Cancer 51, 266-273 (1992).
Goldenberg, David M., et al., “Targeting, Dosimetry, and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody” Journal of Clinical Oncology, vol. 9, No. 4 (Apr. 1991), pp. 548-564.
Stewart, J. Simon W., et al., “Clearance of 131I-labeled Murine Monoclonal Antibody from Patients' Blood by Intravenous Human Anti-Murine Immunoglobulin Antibody” Cancer Research 50, 563-567, Feb. 1, 1990.
Blumenthal, Rasalyn D. et al., “Reduction by Anti-Antibody Administration of the Radiotxicity Associated with 131I-Labeled Antibody to Carcinoembryonic Antigen in Cancer Radioimmunotherapy” Journal of the National Cancer Institute vol. 81, No. 3, Feb. 1989.
Pimm, M. V., et al., “The Influence of Syngeneic Anti-Idiotypic Antibody on the Blodistribution of an anti-tumour monoclonal Antibody in Balb/c Mice” Int. J. Cancer: 43, 147-151 (1989).
Sharkey, Robert M., et al., “Factors Influencing Anti-Antibody Enhancement of Tumor Targeting with Antibodies in Hamsters with Human Colonic Tumor Xenografts” Cancer Research 48, 2005-2009, Apr. 15, 1988.
Goldenberg, David M., et al., “Anti-Antibody Enhancement of Iodine-131 Anti-CEA Radioimmunodetection in Experimental and Clinical Studies” The Journal of Nuclear Medicine, vol. 28, No. 10, Oct. 1987, pp. 1604-1610.
Sharkey, Robert M., et al. “Clinical Evaluation of Tumor Targeting with a High Affinity, Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14” Cancer Mar. 15, 1993, vol. 71, No. 6, pp. 2082-2096.
Behr, Thomas, et al., “High-Linear Energy Transfer (LET) a versus Low-LET B Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model1” Cancer Research59, 2635-2643, Jun. 1, 1999, XP-000982262.
Govindan, Serengulam V., et al., “90Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution Studies” Bioconjugate Chem., vol. 9, No. 6, 1998, 773-782 XP-000982306.
Casey, J. L., et al., “Clearence of yttrium-90-labelled anti-tumour antibodies with antibodies raised against th
Behr Thomas M.
Goldenberg David M.
Center For Molecular Medicine and Immunology
Faegre & Benson LLP
Hartley Michael G.
Samala Jagadishwar R.
LandOfFree
Alpha or beta emitters attached to fragments in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha or beta emitters attached to fragments in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha or beta emitters attached to fragments in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809688